Switch theme
Sign up to access all valuation multiples
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
1998
7.4K+
LTM Revenue $2.2B
LTM EBITDA $381M
$3.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Enovis has a last 12-month revenue (LTM) of $2.2B and a last 12-month EBITDA of $381M.
In the most recent fiscal year, Enovis achieved revenue of $2.1B and an EBITDA of -$481M.
Enovis expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Enovis valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.2B | XXX | $2.1B | XXX | XXX | XXX |
| Gross Profit | $1.3B | XXX | $1.2B | XXX | XXX | XXX |
| Gross Margin | 59% | XXX | 56% | XXX | XXX | XXX |
| EBITDA | $381M | XXX | -$481M | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | -23% | XXX | XXX | XXX |
| EBIT | $261M | XXX | -$103M | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | -5% | XXX | XXX | XXX |
| Net Profit | $165M | XXX | -$825M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | -39% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.3B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Enovis's stock price is $31.
Enovis has current market cap of $1.8B, and EV of $3.2B.
See Enovis trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.2B | $1.8B | XXX | XXX | XXX | XXX | $2.92 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Enovis has market cap of $1.8B and EV of $3.2B.
Enovis's trades at 1.5x EV/Revenue multiple, and -6.7x EV/EBITDA.
Equity research analysts estimate Enovis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Enovis has a P/E ratio of 10.8x.
See valuation multiples for Enovis and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
| EV (current) | $3.2B | XXX | $3.2B | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 8.4x | XXX | -6.7x | XXX | XXX | XXX |
| EV/EBIT | 12.3x | XXX | -31.0x | XXX | XXX | XXX |
| EV/Gross Profit | 2.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 10.8x | XXX | -2.2x | XXX | XXX | XXX |
| EV/FCF | -641.5x | XXX | -47.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEnovis's last 12 month revenue growth is 6%
Enovis's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Enovis's rule of 40 is 16% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Enovis's rule of X is 33% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Enovis and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | -23% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 51% | XXX | XXX | XXX |
| Rule of 40 | 16% | XXX | -17% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 33% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 61% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Enovis acquired XXX companies to date.
Last acquisition by Enovis was XXXXXXXX, XXXXX XXXXX XXXXXX . Enovis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Enovis founded? | Enovis was founded in 1998. |
| Where is Enovis headquartered? | Enovis is headquartered in United States of America. |
| How many employees does Enovis have? | As of today, Enovis has 7.4K+ employees. |
| Is Enovis publicy listed? | Yes, Enovis is a public company listed on NYS. |
| What is the stock symbol of Enovis? | Enovis trades under ENOV ticker. |
| When did Enovis go public? | Enovis went public in 2008. |
| Who are competitors of Enovis? | Similar companies to Enovis include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Enovis? | Enovis's current market cap is $1.8B |
| What is the current revenue of Enovis? | Enovis's last 12 months revenue is $2.2B. |
| What is the current revenue growth of Enovis? | Enovis revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Enovis? | Current revenue multiple of Enovis is 1.5x. |
| Is Enovis profitable? | Yes, Enovis is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Enovis? | Enovis's last 12 months EBITDA is $381M. |
| What is Enovis's EBITDA margin? | Enovis's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Enovis? | Current EBITDA multiple of Enovis is 8.4x. |
| What is the current FCF of Enovis? | Enovis's last 12 months FCF is -$5.0M. |
| What is Enovis's FCF margin? | Enovis's last 12 months FCF margin is 0%. |
| What is the current EV/FCF multiple of Enovis? | Current FCF multiple of Enovis is -641.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
